Trial Profile
Dose-finding and Phase II study of the Combination of Bevacizumab rhuMAb VEGF plus low- dose Immunotherapy and Chemotherapy in patients with metastatic Renal Cell Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Sep 2015
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Aldesleukin; Fluorouracil; Gemcitabine; Interferon alpha-2a
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 26 May 2011 New trial record